These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1598588)

  • 1. Galactose oxidation in the design of immunogenic vaccines.
    Zheng B; Brett SJ; Tite JP; Lifely MR; Brodie TA; Rhodes J
    Science; 1992 Jun; 256(5063):1560-3. PubMed ID: 1598588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galactose oxidation as a potent vaccine adjuvant strategy. Efficacy in murine models and in protection against a bovine parasitic infection.
    Rhodes J; Zheng B; Morrison CA
    Ann N Y Acad Sci; 1995 May; 754():169-86. PubMed ID: 7625651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells.
    Song XT; Evel-Kabler K; Rollins L; Aldrich M; Gao F; Huang XF; Chen SY
    PLoS Med; 2006 Jan; 3(1):e11. PubMed ID: 16381597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galactose receptors and presentation of HIV envelope glycoprotein to specific human T cells.
    Manca F
    J Immunol; 1992 Apr; 148(7):2278-82. PubMed ID: 1312106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
    Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
    J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ag85B of mycobacteria elicits effective CTL responses through activation of robust Th1 immunity as a novel adjuvant in DNA vaccine.
    Takamura S; Matsuo K; Takebe Y; Yasutomi Y
    J Immunol; 2005 Aug; 175(4):2541-7. PubMed ID: 16081827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of immune responses to an HIV gp120 DNA vaccine by fusion to TNF alpha cDNA.
    Nimal S; Heath AW; Thomas MS
    Vaccine; 2006 Apr; 24(16):3298-308. PubMed ID: 16464521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles.
    Sabhnani L; Manocha M; Sridevi K; Shashikiran D; Rayanade R; Rao DN
    FEMS Immunol Med Microbiol; 2003 Oct; 38(3):215-29. PubMed ID: 14522457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of neuraminidase and galactose oxidase on murine lymphocytes. II. Induction of T suppressor cells.
    Kuppers RC; Henney CS
    J Immunol; 1979 May; 122(5):1834-41. PubMed ID: 312852
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of the patterns of antibody recall responses to HIV-1 gp120 and hepatitis B surface antigen in immunized mice.
    Yu HT; Wang JY; Tian D; Wang MX; Li Y; Yuan L; Chen WJ; Li D; Zhuang M; Ling H
    Vaccine; 2016 Dec; 34(50):6276-6284. PubMed ID: 27843002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.
    Haynes BF; Arthur LO; Frost P; Matthews TJ; Langlois AJ; Palker TJ; Hart MK; Scearce RM; Jones DM; McDanal C
    J Exp Med; 1993 Mar; 177(3):717-27. PubMed ID: 7679708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
    Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
    Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An interferon gamma-gp120 fusion delivered as a DNA vaccine induces enhanced priming.
    Nimal S; McCormick AL; Thomas MS; Heath AW
    Vaccine; 2005 Jun; 23(30):3984-90. PubMed ID: 15917120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W; Ren L; Jin N
    J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition.
    Vahlne A; Horal P; Eriksson K; Jeansson S; Rymo L; Hedström KG; Czerkinsky C; Holmgren J; Svennerholm B
    Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10744-8. PubMed ID: 1961741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase in the immunogenicity of HIV peptide antigens by chemical linkage to polytuftsin (TKPR40).
    Gokulan K; Khare S; Rao DN
    DNA Cell Biol; 1999 Aug; 18(8):623-30. PubMed ID: 10463058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of neuraminidase and galactose oxidase on murine lymphocytes. I. Evidence for the differential delivery of signal(s) leading to cell proliferation and the differentiation of cytotoxic T cells.
    Kuppers RC; Henney CS
    J Immunol; 1977 Dec; 119(6):2163-71. PubMed ID: 303259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
    McNicholl JM; Bond KB; Ruhadze ER; Olsen MR; Takayama K; Hunter RL
    AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1457-71. PubMed ID: 9824324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring the Adjuvant Activity of RNA Vaccines.
    Pardi N; Weissman D
    Methods Mol Biol; 2017; 1499():143-153. PubMed ID: 27987147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.